Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TTX-030 |
| Trade Name | |
| Synonyms | TTX030|TTX 030 |
| Drug Descriptions |
TTX-030 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound ENTPD1 (CD39), resulting in decreased ATP hydrolysis, which potentially leads to activation of T-lymphocytes and anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5012). |
| DrugClasses | Adenosine Targeting 24 CD39 Antibody 5 |
| CAS Registry Number | NA |
| NCIT ID | C162693 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin + TTX-030 | Budigalimab Fluorouracil Leucovorin Oxaliplatin TTX-030 | 0 | 0 |
| Budigalimab + Gemcitabine + Nab-paclitaxel + TTX-030 | Budigalimab Gemcitabine Nab-paclitaxel TTX-030 | 0 | 1 |
| Budigalimab + TTX-030 | Budigalimab TTX-030 | 0 | 0 |
| Docetaxel + TTX-030 | Docetaxel TTX-030 | 0 | 1 |
| Gemcitabine + Nab-paclitaxel + TTX-030 | Gemcitabine Nab-paclitaxel TTX-030 | 0 | 2 |
| Gemcitabine + TTX-030 | Gemcitabine TTX-030 | 0 | 0 |
| Pembrolizumab + TTX-030 | Pembrolizumab TTX-030 | 0 | 1 |
| TTX-030 | TTX-030 | 0 | 1 |